Phase I human study and preclinical evaluations of OcuRing™-K showed no treatment-related safety concerns, supporting ...
Bacterial Conjunctivitis Drugs Market is expected to reach US$ 4.9 Billion by 2036, Driven by Increasing Prevalence of Eye ...
AptarGroup, Inc. , a global leader in drug delivery and consumer product dosing, dispensing and protection technologies, announced that its innovative nasal vaccine delivery solutions, LuerVax® and ...
A profound transformation is taking place in therapeutic discovery, development, and delivery.2026 will be a pivotal year for ...
Orphan Drug Designation applies to approximately 50,000 Patients who predominantly suffer from severe chronic pain due to hereditary neuronal sodium ion channel mutationsAdolore's Kv7 voltage-gated ...
In October 2025, Case Comprehensive Cancer Center announced a clinical trial is to see if shorter Photodynamic Therapy (PDT) ...
The FDA has cleared a mobile application that will connect with a next-generation multiple daily injection automated insulin ...
Sanofi may rebid for Ocular Therapeutix, Inc. to boost retinal therapeutics ahead of Dupixent patent expiry. Click for more ...
The drug targets a specific mutation that applies to only 2% of ALS patients. A new drug may slow progression of -- and even reverse -- symptoms of a rare form of amyotrophic lateral sclerosis, or ALS ...
46 new molecular entities cleared the agency’s hurdles last year, 4 fewer than in 2024 ...
The discovery of a novel target can result in exceptionally successful classes of anticancer drugs. For example, the combined global sales in 2024 of PD1–PDL1 inhibitors — for which the first-in-class ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback